Replies to post #214 on Santarus Inc (SNTS)

[surf1944]

2:43PM Santarus confirms appellate court reversal in part of ZEGERID invalidity decision (halted) (SNTS) 6.39 +0.21 : Co confirmed that the U.S. Court of Appeals for the Federal Circuit reversed in part a lower court decision of invalidity involving certain asserted patent claims covering ZEGERID(R) Capsules and ZEGERID Powder for Oral Suspension. The Federal Circuit found that certain claims of asserted U.S. Patent numbers 6,780,882 and 7,399,772, which Par Pharmaceutical (PRX). had been found to infringe, were not invalid due to obviousness. The Federal Circuit also upheld the District Court's finding that there was no inequitable conduct. The case will be remanded back to the U.S. District Court for the District of Delaware for further proceedings consistent with the appellate decision. We plan to aggressively pursue all remedies available to us, including damages as well as seeking an order halting further sales of Par's generic product."